Downstream processing of nanoplexes, including viruses, virus-like particles, and bacteriophages, poses unique challenges due to the complexity of the starting material, diverse purification methods, regulatory requirements, and the need for efficient monitoring tools. This review focuses on the chromatography-based analytical methods essential for monitoring and optimizing nanoplex production, particularly for vaccines, gene therapy vectors, and bacteriophages.
The use of purified virus preparations in vaccines and gene therapy vectors has gained momentum, with over 1900 approved gene therapy clinical trials worldwide. Bacteriophages, once overshadowed by antibiotics, are now being reconsidered for their potential in combating bacterial infections amidst increasing antibiotic resistance. The downstream processing of virus-based biopharmaceuticals faces challenges due to the large size of viruses compared to traditional protein-based molecules, necessitating specialized purification techniques.
Traditional purification methods like density gradient ultracentrifugation and precipitation have limitations in scalability, purity, and economics. The development of advanced chromatography media, such as CIM monolithic columns, has revolutionized virus purification by providing larger surface areas accessible to nanoparticles, efficient mass transfer, high dynamic binding capacity, and superior resolution compared to traditional methods.
Chromatographic analytical methods play a crucial role in monitoring virus production processes, ensuring product reproducibility and quality. The FDA’s Process Analytical Technology (PAT) initiative emphasizes real-time monitoring of production processes, driving the adoption of rapid chromatographic methods for in-process and final product control. These methods, based on HPLC, offer precise quantification, purity assessment, and real-time process insights, reducing time bottlenecks associated with traditional biological assays.
The downstream processing scheme for viruses typically involves clarification, concentration, chromatography-based purification, and a final polishing step for impurity removal and formulation. Charge-specific chromatography, utilizing CIM monolithic columns, is commonly employed for efficient virus purification by exploiting differences in surface charge distribution. These methods demonstrate high virus recovery, dynamic binding capacity, and impurity removal, critical for ensuring the safety and efficacy of viral products for therapeutic applications.
Incorporating chromatographic methods for virus quantification, impurity detection, and process monitoring enhances the efficiency, accuracy, and reproducibility of downstream processing. By integrating advanced chromatography tools with traditional biological assays, researchers can achieve a comprehensive characterization of viral products, ensuring compliance with regulatory standards and product specifications. The ability of chromatography to provide rapid, accurate insights into virus production processes underscores its pivotal role in advancing the field of viral therapeutics.
Key Takeaways:
– Advanced chromatography methods, particularly using CIM monolithic columns, are pivotal for efficient downstream processing of viruses in therapeutic applications.
– Chromatographic analytical tools offer real-time monitoring, precise quantification, and impurity detection, enhancing process control and product quality.
– Integration of chromatography with traditional biological assays improves the characterization of viral products, ensuring compliance with regulatory standards.
– The downstream processing scheme for viruses involves multiple steps, including clarification, concentration, chromatography-based purification, and a final polishing step to achieve high purity and efficacy.
Tags: gene therapy, downstream, chromatography, clinical trials, process development, formulation, cell culture, filtration, regulatory, process analytical technology
Read more on pmc.ncbi.nlm.nih.gov